Financial Modelling

In MedTech, financial models aren't spreadsheets filled with optimistic projections. They're survival tools that map the treacherous path from prototype to profitable product. Build your model on wishful thinking, and you'll run out of cash precisely when regulatory approval feels within reach. Build it on brutal realism and you'll navigate the inevitable delays, cost overruns, and the kind of market resistance that destroys underfunded competitors.

The difference between companies that reach the market and those that fail isn't usually technical merit. It's whether founders understood the true cost of development, planned for delays, priced products realistically, and raised capital before desperation limited their options. Your financial model will prepare you for multiple futures, quantifying risks, and ensure you have resources to survive when your plans become reality.

Modelling approval delays

Regulatory approval timelines quoted in industry reports represent best-case scenarios for straightforward devices with cooperative regulators and perfect submissions. Your device will face additional information requests, testing requirements, or committee reviews that can extend timelines by months or years.

Reimbursement approval will add another layer of uncertainty. Achieving regulatory clearance doesn't mean payers immediately cover your device. Health technology assessment processes, reimbursement negotiations, and coverage decisions can extend 12 to 24 months beyond regulatory approval. During this period, you may experience limited commercial traction because hospitals and clinics are unlikely to adopt devices that patients must pay for out of pocket.

The biggest financial planning mistake we see is underestimating the gap between regulatory approval and commercial revenue. Companies celebrate CE mark or FDA clearance, then discover they need another 18 months and several million pounds to achieve reimbursement coverage to make their device commercially viable.

_{Professor Sir John Bell, Regius Professor of Medicine at Oxford University}So, build multiple timeline scenarios into your financial model. While the optimistic case assumes everything proceeds smoothly, the base case will add realistic delays at each stage (just make sure your funding runway extends way beyond even the most pessimistic case).

The hidden costs of clinical trials

Clinical trial budgets that only account for obvious expenses (like principal investigator fees and patient recruitment) often underestimate true costs by 40% to 60%. Hidden expenses can include contract research organisation fees, clinical monitoring visits, data management systems, statistical analysis, regulatory consulting, site initiation, patient travel reimbursement, adverse event investigation, and protocol amendments.

Contract research organisations (CROs) charge substantial fees for managing trials. Site monitoring visits occur quarterly or more frequently. Data management systems cost tens of thousands per year. Statistical analysis at trial completion can exceed £50,000 for complex studies. Each protocol amendment triggered by safety concerns or recruitment challenges costs £20,000 to £100,000.

Patient recruitment often requires multiple strategies beyond initial plans. When initial projections prove optimistic, you'll need advertising campaigns, recruitment agencies, expanded site networks, and extended enrollment periods. Each recruitment month adds significant cash burn across all trial infrastructure. Expect your model trial to cost twice your initial estimate. Include explicit line items for monitoring, data management, statistical analysis, and protocol amendments. These pessimistic assumptions will protect you when reality exceeds your original expectations.

Scaling cost surprises

Cost of goods sold behaves non-intuitively as production volumes increase. Founders assume costs decrease with volume through economies of scale. While sometimes they do, most often they won't, at least initially.

Your sterilisation costs can spike with volume. Contract sterilisers charge per batch, and batch sizes have physical limits. By doubling your production, this might require more than double the sterilisation expense if you exceed batch capacity. Logistics and distribution costs increase with geographic expansion. Shipping to 50 hospitals costs more per unit than shipping to five hospitals due to smaller shipment sizes and more complex distribution networks.

Know that quality control and testing expenses don't scale linearly. Regulatory compliance in multiple jurisdictions requires documentation, labelling, and testing variations that add cost without adding volume efficiencies.

MedTech founders consistently underestimate how costs behave at scale. They model 40% gross margins based on prototype costs, then discover that manufacturing, sterilisation, quality testing, regulatory compliance, and distribution at commercial volumes leave them with 15% margins.

_{Dr Hermann Requardt, former Member of the Board of Management at Siemens Healthineers}

Build detailed cost models at multiple production volumes. Include all direct costs, like materials, labour, sterilisation, packaging, and shipping. Add any indirect costs, such as quality testing, regulatory compliance, and inventory carrying costs. Then model gross margins at 100 units, 1,000 units, and 10,000 units annually.

Pricing realism

Founders often price devices based on cost-plus models or what they need to charge to achieve target returns. Markets don't care about your cost structure or return requirements. They care about clinical value, competitive alternatives, and payer willingness to pay.

Research payer reimbursement thresholds for your device category. NHS England, major European health systems, and US Medicare publish fee schedules showing what they pay for comparable devices and procedures. If existing solutions are reimbursed at £500 and your device offers modest improvements, you won't achieve £2,000 pricing regardless of development costs.

Benchmark your competitor pricing carefully. Hospital procurement teams will negotiate aggressively and have excellent market intelligence. Health economic analysis becomes mandatory for premium-priced devices. You need to demonstrate that higher upfront costs will generate savings for them through reduced complications, shorter procedures, or faster recovery.

Avoiding funding cliffs

The worst time to raise capital is when you desperately need it. Investors will smell your desperation and, in return, create punitive terms. Negotiations extend for months while your cash position deteriorates. So, plan any fundraising 12 to 18 months before cash depletion. This timeline provides a buffer for slower-than-expected processes and negotiation of favourable terms. Model your cash position monthly over the next 36 months under multiple scenarios, and identify when each scenario will exhaust your cash reserves. Back up 18 months from that date to establish fundraising timelines.

Fundraising itself consumes significant management time and occasionally requires external advisors, lawyers, and due diligence support that costs hundreds of thousands of pounds. Consider also that funding markets fluctuate. Maintaining excess runway provides flexibility to delay raises when markets are unfavourable.

Quantify uncertainty through simulation

Deterministic financial models showing single projections will misrepresent your reality. Monte Carlo simulation quantifies uncertainty by running thousands of scenarios with randomised inputs. Model regulatory approval probability at 70% with a timeline ranging from 18 to 36 months. Model pricing between £800 and £1,500 based on competitive pressure. Model cost overruns between 20% and 80% of the budget. This analysis will reveal your true risk exposure. You might discover, for example, that 30% of scenarios result in cash depletion before achieving commercial revenue. Simulation also identifies which variables matter most, allowing you to focus risk mitigation on high-impact factors.

Financial models workshop

With VP Med Ventures, financial modelling will help you quantify scenarios, identify risks, and ensure you have sufficient resources to survive when plans encounter reality. The companies that reach the market won’t necessarily be those with superior technology. They're the ones with sufficient capital to survive the inevitable delays and challenges that development entails.

Waypoint checklist

Keep in mind the following points when you check your financial model:

• Approval delays with model cash burn during regulatory/reimbursement limbo.
• Trial costs, which include hidden expenses.
• Scaling costs, where COGS can spike with volume.
• Pricing realism means you need to align with payer thresholds and competitor benchmarks.
• Funding cliffs, so make sure to plan for raises 12+ months before cash runs out.
• Make sure to use Monte Carlo simulations to model any uncertainty.